SCHEMBL25822284

SCHEMBL25822284

CNC(=O)CCCOc1cccc(OCCNN)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
PDK2 Q15119 2/20 0.50
NSD2 O96028 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MTNR1A P48039 1/20 0.48
MTNR1B P49286 1/20 0.48
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
P2RY12 Q9H244 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25820387 0.89 KDM4E (0.60) KDM4ESMN1; SMN2PDK2NSD2ALDH1A1
SCHEMBL2206370 0.86 SMN1; SMN2 (0.52) KDM4ESMN1; SMN2PDK2NSD2ALDH1A1
SCHEMBL29818936 0.86 SMN1; SMN2 (0.52) KDM4ESMN1; SMN2PDK2NSD2ALDH1A1
SCHEMBL25822303 0.85 KDM4E (0.49) KDM4ESMN1; SMN2PDK2NSD2ALDH1A1
SCHEMBL27439170 0.84 KMT2A (0.55) KDM4ESMN1; SMN2PDK2HPGDMEN1
SCHEMBL25822296 0.82 CYP2D6 (0.49) KDM4ESMN1; SMN2PDK2NSD2ALDH1A1
SCHEMBL353032 0.79 HPGD (0.63) SMN1; SMN2ALDH1A1HPGDMEN1KMT2A
SCHEMBL8901248 0.78 KDM4E (0.62) KDM4ESMN1; SMN2NSD2ALDH1A1HPGD
SCHEMBL29818817 0.77 CNR1 (0.52) SMN1; SMN2PDK2HPGDMTNR1AMTNR1B
SCHEMBL19291537 0.77 HPGD (0.54) KDM4ESMN1; SMN2NSD2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER KDM4E 2227/4885SMN1; SMN2 39/4885PDK2 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.